Research Grade eflumenibep alfa (HC100016)

Name: Research Grade eflumenibep alfa
Brand: abinScience
SKU: HC100016
Price: 370 USD
Availability: InStock

Price(USD): --

Spec:

Number:

Get quote

Overview

Catalog No.	HC100016
Description	eflumenibep alfa (HC100016) is a research-grade recombinant antibody targeting SPINK2. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research.
Species reactivity	Human
Applications	Functional assay
Clonality	Monoclonal
Isotype	SPINK2-Fc
Expression system	Mammalian cells
Nature	Recombinant
Target	SPINK2
Endotoxin level	< 10 EU/mg as determined by LAL method.
Purity	>95% as determined by SDS-PAGE.
Accession	P20155
Storage buffer	0.01M PBS pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	CAS: 2418159-10-9
Background	Serine protease inhibitor Kazal-type 2 is a ~9 kDa protein. As a strong inhibitor of acrosin, it is required for normal spermiogenesis. It probably hinders premature activation of proacrosin and other proteases, thus preventing the cascade of events leading to spermiogenesis defects. May be involved in the regulation of serine protease-dependent germ cell apoptosis. It also inhibits trypsin. 1. Kherraf, ZE. et al. (2017) EMBO molecular medicine 9, 1132-1149. PMID: 28554943
Note	For research use only. Not suitable for clinical or therapeutic use.

Images

References

Datasheet

Download SDS PDF

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

Concentration

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

V₁ (Stock Vol.)

Working Solution

C₂ (Working Conc.)

V₂ (Working Vol.)

Overview